Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Finished Goods (2019 - 2025)

Karyopharm Therapeutics' Finished Goods history spans 7 years, with the latest figure at $430000.0 for Q4 2025.

  • For Q4 2025, Finished Goods fell 9.85% year-over-year to $430000.0; the TTM value through Dec 2025 reached $430000.0, down 9.85%, while the annual FY2025 figure was $430000.0, 9.85% down from the prior year.
  • Finished Goods reached $430000.0 in Q4 2025 per KPTI's latest filing, down from $433000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $991000.0 in Q3 2022 to a low of $114000.0 in Q1 2021.
  • Average Finished Goods over 5 years is $547600.0, with a median of $455000.0 recorded in 2024.
  • Peak YoY movement for Finished Goods: surged 424.05% in 2021, then crashed 44.02% in 2025.
  • A 5-year view of Finished Goods shows it stood at $414000.0 in 2021, then surged by 135.75% to $976000.0 in 2022, then dropped by 22.34% to $758000.0 in 2023, then plummeted by 37.07% to $477000.0 in 2024, then dropped by 9.85% to $430000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Finished Goods are $430000.0 (Q4 2025), $433000.0 (Q3 2025), and $349000.0 (Q2 2025).